US2004122019A1PendingUtilityA1

Benzoylguanidine salt and hydrates thereof

52
Assignee: BOEHRINGER INGELHEIM PHARMAPriority: Feb 15, 2001Filed: Dec 9, 2003Published: Jun 24, 2004
Est. expiryFeb 15, 2021(expired)· nominal 20-yr term from priority
C07D 207/416C07D 403/02C07D 207/34
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

4-[4-(2-pyrrolylcarbonyl)-1-piperazinyl]-3-trifluoromethylbenzoylguanidine hydrochloride and its hydrates, processes for preparing this benzoylguanidine salt and its hydrates, pharmaceutical compositions containing this benzoylguanidine salt and its hydrates, and its use in treating diseases, particularly those in which inhibition of the cellular Na + /H + exchange is of therapeutic benefit.

Claims

exact text as granted — not AI-modified
We claim:  
     
         1 . 4-[4-(2-pyrrolylcarbonyl)-1-piperazinyl]-3-trifluoromethylbenzoylguanidine hydrochloride 1 
       
         
           
           
               
               
           
         
       
     
     
         2 . A pharmaceutical composition comprising: 
 (a) the compound according to  claim 1;  and    (b) a pharmaceutically acceptable excipient.    
     
     
         3 . A method of treating diseases in which inhibition of the cellular Na + /H +  exchange is of therapeutic benefit in a patient in need thereof, the method comprising administering to the patient an effective amount of the compound according to  claim 1 .  
     
     
         4 . The method according to  claim 3 , wherein the compound according to  claim 1  is administered in the form of an aqueous injectable solution, a tablet, a suppository, an ointment, a transdermal plaster, an inhalation aerosol, or a nasal spray.  
     
     
         5 . A method of treating diseases in which inhibition of the cellular Na + /H +  exchange is of therapeutic benefit in a patient in need thereof, the method comprising administering to the patient an effective amount of a hydrate of 4-[4-(2-pyrrolylcarbonyl)-1-piperazinyl]-3-trifluoromethylbenzoylguanidine hydrochloride 1  
       
         
           
           
               
               
           
         
       
     
     
         6 . A method of treating diseases in which inhibition of the cellular Na + /H +  exchange is of therapeutic benefit in a patient in need thereof, the method comprising administering to the patient an effective amount of a monohydrate of 4-[4-(2-pyrrolylcarbonyl)-1-piperazinyl]-3-trifluoromethylbenzoylguanidine hydrochloride 1  
       
         
           
           
               
               
           
         
       
     
     
         7 . A method of treating diseases in which inhibition of the cellular Na + /H +  exchange is of therapeutic benefit in a patient in need thereof, the method comprising administering to the patient an effective amount of a hemihydrate of 4-[4-(2-pyrrolylcarbonyl)-1-piperazinyl]-3-trifluoromethylbenzoylguanidine hydrochloride 1  
       
         
           
           
               
               
           
         
       
     
     
         8 . The method according to  claim 5 , wherein the a hydrate of 4-[4-(2-pyrrolylcarbonyl)-1-piperazinyl]-3-trifluoromethylbenzoylguanidine hydrochloride 1 is administered in the form of an aqueous injectable solution, a tablet, a suppository, an ointment, a transdermal plaster, an inhalation aerosol, or a nasal spray.  
     
     
         9 . The method according to  claim 6 , wherein the monohydrate of 4-[4-(2-pyrrolylcarbonyl)-1-piperazinyl]-3-trifluoromethylbenzoylguanidine hydrochloride 1 is administered in the form of an aqueous injectable solution, a tablet, a suppository, an ointment, a transdermal plaster, an inhalation aerosol, or a nasal spray.  
     
     
         10 . The method according to  claim 7 , wherein the 4-[4-(2-pyrrolylcarbonyl)-1-piperazinyl]-3-trifluoromethylbenzoylguanidine hydrochloride 1 is administered in the form of an aqueous injectable solution, a tablet, a suppository, an ointment, a transdermal plaster, an inhalation aerosol, or a nasal spray.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.